| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $44.4M | -22.3% |
| SG&A Expense | $18.0M | -14.6% |
| Operating Income | -$62.4M | +20.2% |
| Net Income | -$49.6M | +25.8% |
| EPS (Basic) | -$0.88 | +26.1% |
| EPS (Diluted) | -$0.88 | +26.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $22.6M | +6.4% |
| Short-term Investments | $222.9M | -14.5% |
| Current Assets | $248.0M | -12.8% |
| Total Assets | $252.1M | -13.0% |
| Current Liabilities | $8.5M | -12.1% |
| Total Liabilities | $10.0M | -16.4% |
| Stockholders' Equity | $242.1M | -12.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$43.1M | +26.4% |
| Capital Expenditures | $340K | +32.8% |
| Investing Cash Flow | $44.0M | -16.3% |
| Financing Cash Flow | $513K | -29.1% |
| Free Cash Flow | -$43.4M | +26.1% |